Ovarian Cancer Clinical Trials in Tennessee

Showing 121-140 of 253 trials

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric Cancer+9 more

ADC Therapeutics S.A.78 participantsStarted Nov 2018

Palo Alto, California, United States • New Haven, Connecticut, United States • Portland, Oregon, United States +6 more locations

UNKNOWNPhase 1/229 miles

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

NCT04780217

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors

Solid TumorHepatocellular CarcinomaColorectal Cancer+3 more

ImmVira Pharma Co. Ltd42 participantsStarted Aug 2021

Phoenix, Arizona, United States • Plantation, Florida, United States • Greenville, South Carolina, United States +3 more locations

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Ovarian Cancer Trials in Other Cities

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Other Conditions in Tennessee